OSR Holdings, Inc. (OSRH) - Q1 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2025. OSR Holdings, Inc. is a global life sciences holding company based in South Korea, focusing on oncology and immunology. The quarter was defined by the consummation of a business combination on February 14, 2025, transforming the entity from a SPAC into an operating company with subsidiaries including VAXIMM AG, RMC Co., Ltd., and Darnatein Co., Ltd.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Net Sales | $761,272 | $910,225 |
| Gross Profit | $168,686 | $239,802 |
| Gross Margin | 22.2% | 26.3% |
| Operating Loss | $(2,917,826) | $(3,302,528) |
| Net Loss | $(11,392,814) | $(3,355,366) |
| Cash and Equivalents (End of Period) | $1,595,697 | $512,435 |
| Total Debt (Short-term + Long-term) | $4,710,699 | $2,297,411 |
| Accumulated Deficit | $(30,565,877) | $(13,852,175) |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 16% to $761k, primarily due to the termination of a key customer relationship (Penumbrain) for the RMC subsidiary in late 2024.
- Significant Net Loss Increase: Net loss widened to $11.4 million (from $3.4 million) driven by a one-time $8.5 million charge for merger and acquisition costs associated with the February 2025 business combination.
- SG&A Reduction: Selling, general, and administrative expenses decreased 13% to $3.1 million, largely due to a $623k reduction in amortization expenses following a change in the useful life of certain intangible assets.
- Liquidity Improvement: Cash and cash equivalents increased to $1.6 million from $341k at year-end 2024, aided by cash acquired in the business combination and short-term borrowings.
- Debt Increase: Short-term borrowings increased significantly, including the issuance of $2.6 million in short-term corporate bonds not present in the prior year.
Outlook, Risks, and Unusual Items
- Merger Costs: The $8.5 million "Other expenses" line item is a non-recurring cost related to the business combination closing on February 14, 2025.
- Revenue Outlook: Management expects revenue to decrease in 2025 until RMC secures new products to replace Penumbra sales. A 2% reimbursement increase by the Korean Health Insurance Review and Assessment Service (HIRA) starting April 1, 2025, may partially offset currency headwinds.
- R&D Guidance: R&D expenses are projected to range from $2.5M to $3.0M per quarter starting mid-2025, potentially rising to $5.0M–$6.0M per quarter.
- Capital Raising: The company entered into an Equity Line of Credit (ELOC) agreement with White Lion Capital for up to $80 million to fund operations. Additionally, a $1.11 million convertible note was issued in May 2025.
- Legal Proceedings: A civil action was filed in March/May 2025 by Benjamin Securities, Inc., seeking $425,000 in brokerage fees.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of March 31, 2025, due to identified material weaknesses in internal control over financial reporting.
Investor Verification Checklist
- Verify the sustainability of the $8.5 million merger cost charge and confirm it is non-recurring.
- Assess the timeline and probability of RMC securing replacement products to offset the loss of the Penumbra customer.
- Review the terms of the $80 million ELOC and $1.11 million convertible note with White Lion Capital for dilution risks and repayment obligations.
- Monitor the status of the $425,000 lawsuit filed by Benjamin Securities, Inc.
- Evaluate the remediation plan for the material weaknesses in internal controls over financial reporting.
- Confirm the impact of the Korean Won (KRW) depreciation on future gross margins and the effectiveness of the HIRA reimbursement increase.